<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
<url><loc>https://majorhealthnews.com/press-releases/tvardi-therapeutics-advances-next-generation-oral-stat3-inhibitor-tti-109-toward-ind-in</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T13:30:59.651Z</news:publication_date><news:title>Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/biohavens-novel-fgfr3-directed-adc-with-proprietary-topoix-payload-bhv-1530-shows</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T12:45:59.140Z</news:publication_date><news:title>Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/kazia-therapeutics-announces-filing-of-annual-report-on-form-20-f-for-fiscal-year-ended</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T12:07:10.175Z</news:publication_date><news:title>Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/eloxx-pharmaceuticals-announces-publication-of-phase-2a-exaluren-data-in-nonsense</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T21:07:55.436Z</news:publication_date><news:title>Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/racura-oncology-receives-first-site-approval-for-seamless-phase-2b3-emili-trial-of-rc220</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T12:54:10.183Z</news:publication_date><news:title>Racura Oncology Receives First Site Approval for Seamless Phase 2b/3 EMILI Trial of RC220 in Relapsed or Refractory Acute Myeloid Leukemia</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/biolinerx-enters-into-dollar56-million-royalty-monetization-transaction-with-soleus</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T12:19:16.294Z</news:publication_date><news:title>BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/lotte-biologics-holds-completion-ceremony-for-songdo-bio-campus</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T11:33:25.840Z</news:publication_date><news:title>LOTTE Biologics Holds Completion Ceremony for Songdo Bio Campus</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/harbour-biomeds-partner-spruce-biosciences-separates-crhx-101-program-into-adrenyx</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T00:20:16.358Z</news:publication_date><news:title>Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/inhibrx-announces-updated-clinical-data-for-ozekibart-inbrx-109-in-ewing-sarcoma</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T22:03:37.036Z</news:publication_date><news:title>Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/labcorp-to-expand-clinical-trial-operations-in-brazil-with-dedicated-kit-assembly-and</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T21:55:51.339Z</news:publication_date><news:title>Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury</news:title></news:news></url>
</urlset>